Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 1:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 195 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Delayed Gastric Emptying Clear all
Completed Phase 1 Interventional

RQ-00000010 for Gastroparesis and Constipation in Parkinson's Disease

NCT02838797
View directory record Official record
Conditions
Parkinson's Disease, Gastroparesis, Constipation
Interventions
RQ-00000010, Placebo
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Henrico, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 8, 2019 · Synced Jun 10, 2026, 1:41 PM EDT
Completed Phase 2 Interventional

Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis

NCT01452815
View directory record Official record
Conditions
Gastroparesis, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Interventions
Placebo, 10mg TZP-102, 20mg TZP-102
Drug
Lead sponsor
Tranzyme, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
31
States / cities
Huntsville, Alabama • Tucson, Arizona • Jonesboro, Arkansas + 27 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2013 · Synced Jun 10, 2026, 1:41 PM EDT
Completed Phase 1Phase 2 Interventional

Study Evaluating the Effect of TC-6499 on Gastric Emptying Time in Diabetic Subjects With Gastroparesis

NCT02187094
View directory record Official record
Conditions
Gastroparesis
Interventions
TC-6499, Placebo
Drug
Lead sponsor
Targacept Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
8
States / cities
Mobile, Alabama • Little Rock, Arkansas • Chula Vista, California + 5 more
Source: ClinicalTrials.gov public record
Updated May 11, 2015 · Synced Jun 10, 2026, 1:41 PM EDT
Terminated Not applicable Interventional Results available

Transcutaneous Electroacupuncture for Gastrointestinal Motility Disorders

NCT04349891
View directory record Official record
Conditions
Gastroparesis
Interventions
Transcutaneous Electroacupuncture, Sham TEA
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 80 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Jun 10, 2026, 1:41 PM EDT
Terminated Phase 3 Interventional Results available

Diabetic Gastroparesis Study 05

NCT03786380
View directory record Official record
Conditions
Gastroparesis
Interventions
Relamorelin 10 μg
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
189
States / cities
Anniston, Alabama • Athens, Alabama • Birmingham, Alabama + 157 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2021 · Synced Jun 10, 2026, 1:41 PM EDT
Completed Not applicable Interventional

Controlled Trial of Gastric Electrical Stimulation in Children

NCT07474415
View directory record Official record
Conditions
Gastroparesis, Functional Dyspepsia, Vomiting Syndrome
Interventions
Temporary Gastric Electrical Stimulation
Device
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
Up to 21 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 15, 2026 · Synced Jun 10, 2026, 1:41 PM EDT
Completed Phase 4 Interventional Results available

Pharmacokinetics of Immediate-Release vs. Delayed-Release Omeprazole in Gastroparesis

NCT00492622
View directory record Official record
Conditions
Gastroparesis, Gastroesophageal Reflux Disease
Interventions
Immediate-release omeprazole, Delayed-release omeprazole
Drug
Lead sponsor
University of Louisville
Other
Eligibility
18 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Jul 27, 2017 · Synced Jun 10, 2026, 1:41 PM EDT
Completed Phase 2 Interventional Results available

Safety, PK and Efficacy of PCS12852 on Gastric Emptying Rate in Patients With Moderate to Severe Gastroparesis

NCT05270460
View directory record Official record
Conditions
Gastroparesis
Interventions
PCS12852, Placebo
Drug
Lead sponsor
Processa Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
9
States / cities
Lomita, California • San Diego, California • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2023 · Synced Jun 10, 2026, 1:41 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Use of EndoFLIP and Manometry Prior to G-POEM

NCT04844190
View directory record Official record
Conditions
Gastroparesis
Interventions
EndoFLIP, Antroduodenal Manometry
Diagnostic Test
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 21, 2025 · Synced Jun 10, 2026, 1:41 PM EDT
Terminated Phase 2 Interventional Results available

A Phase 2 Study of CIN-102 in Adults With Idiopathic and Diabetic Gastroparesis

NCT04026997
View directory record Official record
Conditions
Gastroparesis
Interventions
CIN-102 Dose 1, CIN-102 Dose 2, CIN-102 Dose 3, Placebo
Drug
Lead sponsor
CinDome Pharma, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
19
States / cities
Chula Vista, California • Jacksonville, Florida • Miami, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Jun 10, 2026, 1:41 PM EDT
Terminated Phase 2 Interventional Results available

Self-Propelled Percutaneous Endoscopic GastroJejunostomy (PEG-J)

NCT01551095
View directory record Official record
Conditions
GERD
Interventions
PEGJ tube
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 90 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 30, 2017 · Synced Jun 10, 2026, 1:41 PM EDT
Withdrawn Phase 4 Interventional

Daily Tadalafil and Gastric Emptying Time in Diabetic Gastroparesis

NCT01326117
View directory record Official record
Conditions
Gastroparesis, Diabetic Gastroparesis, Nausea, Vomiting
Interventions
tadalafil
Drug
Lead sponsor
Mark Feinglos
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 28, 2014 · Synced Jun 10, 2026, 1:41 PM EDT
Not yet recruiting No phase listed Observational

Prokinetics and Body Surface Gastric Mapping in Dyspeptic Patients: Baseline and Treatment Effects

NCT06854120
View directory record Official record
Conditions
Gastroparesis, Functional Dyspepsia
Interventions
Gastric Alimetry
Device
Lead sponsor
University of Auckland, New Zealand
Other
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 2, 2025 · Synced Jun 10, 2026, 1:41 PM EDT
Recruiting Phase 2Phase 3 Interventional

Effectiveness of Methods for Pyloric Drainage in esophagecTomY: Botox vs. Pyloromyotomy

NCT06721520
View directory record Official record
Conditions
Esophageal Cancer Surgery, Esophagectomy, Delayed Gastric Emptying Following Procedure, Esophageal Diseases, Esophageal Achalasia, Pylorus Dysfunction, Esophageal Dysmotility
Interventions
Botulinum Toxin A (Botox ), Pyloromyotomy
Biological · Procedure
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Jun 10, 2026, 1:41 PM EDT
Not listed Phase 2 Interventional

Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy of Nimacimab in Patients With Diabetic Gastroparesis

NCT03900325
View directory record Official record
Conditions
Diabetic Gastroparesis
Interventions
Nimacimab, Placebo
Drug
Lead sponsor
Bird Rock Bio, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
5
States / cities
Miami, Florida • Wichita, Kansas • Rochester, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2020 · Synced Jun 10, 2026, 1:41 PM EDT
Completed No phase listed Observational

Gastroparesis Registry 2

NCT01696747
View directory record Official record
Conditions
Gastroparesis, Diabetic Gastroparesis, Idiopathic Gastroparesis
Interventions
Not listed
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
18 Years and older
Enrollment
506 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
6
States / cities
Louisville, Kentucky • Baltimore, Maryland • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2022 · Synced Jun 10, 2026, 1:41 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

GI Neuromuscular Pathology Prospective Registry

NCT02165059
View directory record Official record
Conditions
Gastroparesis
Interventions
Surgical Full Thickness Biopsy
Procedure
Lead sponsor
Indiana University
Other
Eligibility
6 Months to 90 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2025
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 7, 2024 · Synced Jun 10, 2026, 1:41 PM EDT
Suspended Not applicable Interventional

A Study to Evaluate the Safety and Tolerability of Virtual Reality to Treat Gastroparesis

NCT05079568
View directory record Official record
Conditions
Gastroparesis
Interventions
Oculus Go VR headset, Sham Oculus Go VR headset
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Jacsonville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Jun 10, 2026, 1:41 PM EDT
Withdrawn Phase 2 Interventional

Naloxegol for Opioid-Related Gastroparesis

NCT03036891
View directory record Official record
Conditions
Gastroparesis, Opioid Use
Interventions
Naloxegol 25 MG Oral Tablet [Movantik], Placebo Oral Tablet
Drug
Lead sponsor
Temple University
Other
Eligibility
18 Years to 84 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 26, 2020 · Synced Jun 10, 2026, 1:41 PM EDT
Completed Phase 2 Interventional

Phase 2 Study to Evaluate Safety & Efficacy of RM-131 Administered to Patients With Diabetic Gastroparesis

NCT01571297
View directory record Official record
Conditions
Diabetes Mellitus, Diabetes Mellitus Complications, Gastroparesis
Interventions
RM-131, Placebo
Drug
Lead sponsor
Motus Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
30
States / cities
Dothan, Alabama • Tucson, Arizona • North Little Rock, Arkansas + 27 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2016 · Synced Jun 10, 2026, 1:41 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

GEBT Lot-to-Lot and Biological Variability

NCT04772261
View directory record Official record
Conditions
Gastroparesis
Interventions
13C-Spirulina GEBT
Diagnostic Test
Lead sponsor
Cairn Diagnostics
Industry
Eligibility
18 Years to 85 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Brentwood, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 17, 2022 · Synced Jun 10, 2026, 1:41 PM EDT
Terminated Phase 3 Interventional Results available

A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 03

NCT03420781
View directory record Official record
Conditions
Gastroparesis, Diabetes Mellitus
Interventions
Placebo, Relamorelin
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
467 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
161
States / cities
Athens, Alabama • Dothan, Alabama • Foley, Alabama + 126 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2021 · Synced Jun 10, 2026, 1:41 PM EDT
Terminated Phase 2 Interventional Results available

Nutritional Adequacy Therapeutic Enhancement in the Critically Ill. The NUTRIATE Study

NCT01934192
View directory record Official record
Conditions
Gastroparesis
Interventions
GSK962040 50 mg, Metoclopramide 10 mg, Placebo NG, Placebo IV
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 85 Years
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
4
States / cities
Aurora, Colorado • Augusta, Georgia • Louisville, Kentucky + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2017 · Synced Jun 10, 2026, 1:41 PM EDT
Active, not recruiting No phase listed Observational

Vagus Nerve Response in Gastroparesis Patients

NCT04207996
View directory record Official record
Conditions
Gastroparesis
Interventions
Not listed
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Jun 10, 2026, 1:41 PM EDT